Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for malignant mesothelioma

R N Taub1, K H Antman

  • 1Department of Medicine, Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA.

Seminars in Thoracic and Cardiovascular Surgery
|November 14, 1997
PubMed
Summary

Treating malignant mesothelioma (MM) is difficult due to study limitations. Current chemotherapy regimens show modest activity, with ongoing research into new treatments and drug delivery methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2010
Same author

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.

Oncogene·2006
Same author

Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer.

Bone marrow transplantation·2003
Same author

Peritoneal mesothelioma.

Current treatment options in oncology·2002
Same author

New biology and therapies in soft tissue sarcomas.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2002
Same author

Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer.

Journal of the National Cancer Institute. Monographs·2002

Area of Science:

  • Oncology
  • Thoracic Surgery

Background:

  • Malignant mesothelioma (MM) treatment presents significant challenges.
  • Publication bias and difficulties in response assessment complicate research.
  • The natural history of MM is variable, with a generally short duration.

Purpose of the Study:

  • To review the current state of malignant mesothelioma treatment.
  • To highlight challenges in clinical trial design and interpretation.
  • To discuss the efficacy of existing chemotherapeutic agents and future research directions.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of response rates and survival data from cooperative group studies.
  • Discussion of challenges in assessing tumor response due to pleural tumor distribution.

Related Experiment Videos

Main Results:

  • Doxorubicin, cisplatin, and ifosfamide demonstrate modest activity in MM treatment.
  • A Cancer and Leukemia Group B study reported a 24% response rate for cisplatin-based regimens.
  • Survival outcomes were slightly better with doxorubicin-containing combinations.

Conclusions:

  • Chemotherapy offers modest benefits for malignant mesothelioma patients.
  • Larger cooperative group studies are improving data reliability.
  • Ongoing research focuses on novel agents and drug delivery systems for MM.